Jubilant Life Sciences' (Jubilant) Q2FY19 numbers were a mixed bag. While revenues were above I-direct estimates, EBITDA margins were below estimates mainly due to lower-than-expected margins in speciality pharma and LSI segments Revenues grew 38.2% YoY mainly due to 54.1% growth in pharma segment to | 1326 crore led by strong growth in the speciality business, one-off Valsartan sales in generics and consolidation of Pharmacy business. Ex-pharmacy, the segment grew 33%...